Ravindre Panchia to Anti-HIV Agents
This is a "connection" page, showing publications Ravindre Panchia has written about Anti-HIV Agents.
Connection Strength
1,603
-
Preferences for HIV pre-exposure prophylaxis formulations and delivery among young African women: results of a discrete choice experiment. J Int AIDS Soc. 2025 Feb; 28(2):e26422.
Score: 0,128
-
High recent PrEP adherence with point-of-care urine tenofovir testing and adherence counselling among young African women: results from the INSIGHT cohort. J Int AIDS Soc. 2024 Dec; 27(12):e26389.
Score: 0,126
-
Interest in Oral Pre-exposure Prophylaxis Among Men Who Have Sex with Men and Transfeminine Persons in HPTN 075, a Multi-center HIV Prevention Study in Sub-Saharan Africa (2015-2017). AIDS Behav. 2025 Feb; 29(2):411-419.
Score: 0,125
-
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022 05 07; 399(10337):1779-1789.
Score: 0,105
-
Likely clinical depression and HIV-related decline in antiretroviral therapy untreated women who seroconverted during participation in microbicide trials in sub-Saharan Africa. Int J STD AIDS. 2021 06; 32(7):620-628.
Score: 0,098
-
Uptake of antiretroviral treatment and viral suppression among men who have sex with men and transgender women in sub-Saharan Africa in an observational cohort study: HPTN 075. Int J Infect Dis. 2021 Mar; 104:465-470.
Score: 0,097
-
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077. AIDS Behav. 2020 Sep; 24(9):2520-2531.
Score: 0,094
-
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020 07; 7(7):e472-e481.
Score: 0,093
-
Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077. Clin Infect Dis. 2020 01 02; 70(2):319-322.
Score: 0,090
-
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018 11; 15(11):e1002690.
Score: 0,083
-
Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018 11; 18(11):1241-1250.
Score: 0,083
-
Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. PLoS One. 2017; 12(5):e0177281.
Score: 0,075
-
Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr. 2017 Jan 01; 74(1):112-116.
Score: 0,073
-
Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr. 2016 07 01; 72(3):304-9.
Score: 0,071
-
Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. Lancet Infect Dis. 2015 Jul; 15(7):803-9.
Score: 0,065
-
Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet. 2013 Nov 09; 382(9904):1555-63.
Score: 0,059
-
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis. 2013 Nov 15; 208(10):1624-8.
Score: 0,058
-
Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis. Int J Tuberc Lung Dis. 2011 Sep; 15(9):1194-200, i.
Score: 0,050
-
Interest in I-PrEP and Willingness to Participate in Clinical Trials Among Men and Transfeminine Persons Who have Sex with Men in Sub-Saharan Africa: Quantitative and Qualitative Findings from HPTN 075. AIDS Behav. 2024 Jul; 28(7):2361-2377.
Score: 0,030